Table 1. Effects of Dabigatran and Rivaroxaban on TG in PPP (low tissue factor).

Treatment	LT (min)	TTP (min)	PH (nM)	ETP (min x nM)
Control	5.8±0.6	10.6±0.4	117.1±21.2	1453±199
Dabi 250 nM	18.7±2.1***	22.4±2.2***	141.0±24.9	1352±197
Dabi 500 nM	30.4±3.1***	34.9±3.3***	87.8±10.7*	832±63** §
Dabi 1000 nM	40.5±6.2***	49.5±6.7***	22.6±7.2**	118±83** §
Riva 250 nM	15.5±0.3***	31.8±1.2***	34.1±1.0**	621±16** §
Riva 500 nM	17.7±0.5***	30.5±5.3**	19.9±8.2**	343±86*** §
Riva 1000 nM	22.7±2.2***	50.6±3.3***	12.6±1.8***	63±53*** §

TG, thrombin generation triggered by 1 pM recombinant tissue factor; PPP, platelet-poor plasma; Dabi, dabigatran; Riva, rivaroxaban; LT, lag time; TTP, time to peak of TG; PH, peak height of TG; ETP, endogenous thrombin generation potential.

Data are shown as the mean ± SD. * P<0.05, ** P<0.01, and *** P<0.001 vs. control.

^§indicates that, since TG curves did not come down to the baseline within 60 min, ETP values were calculated by setting the start tail at 60min.